Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Company News for Jul 2, 2019

Companies In The News Are: BA,GWR,BIP,PFE,COTY

The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot

The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot

Pfizer's (PFE) Avastin Biosimilar Zirabev Gets FDA Approval

Pfizer (PFE) gets FDA approval for biosimilar Avastin, Zirabev. This is Pfizer's second oncology biosimilar to be approved in United States.

Sarepta Up as Pfizer's DMD Gene Therapy Faces Safety Issues

Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.

Company News for Jul 1, 2019

Companies In The News Are: PFE,NKE,AAPL,STZ

Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger

AbbVie (ABBV) announces definitive deal to buy Allergan (AGN). Bristol-Myers (BMY) set to sell Celgene's Otezla to complete the impending merger.

Swarup Gupta headshot

Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop

The index suffered a disappointing week, declining over three straight trading sessions

Lilly's Study on Higher Doses of Trulicity Meets Endpoint

Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.

Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits

Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.

Conatus' Emricasan Lags Primary Goal in Liver Function Study

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

Pfizer (PFE) Flat As Market Sinks: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $43.76, marking no change from the previous day.

Abbvie Decides to Acquire Allergan

Abbvie Decides to Acquire Allergan

Mark Vickery headshot

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.

Neena Mishra headshot

Why These Innovative Biotech ETFs Are Soaring

Strong M&A activity has sent shares of many small, innovative biotech companies surging

Eldorado to Buy Caesars

Eldorado to Buy Caesars

BioMarin Gets $15M From Pfizer on Talzenna's European Nod

BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

Mark Vickery headshot

U.S. Senate Takes on Big Tech, Plus "Merger Monday"

Eldorado Resorts (ELR) has agreed to buy Caesars (CZR) for $8.6 billion, and a bipartisan bill in the Senate holds Big Tech accountable for monetized user data.

Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

Swarup Gupta headshot

Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up

Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

Stock Market News For Jun 20, 2019

Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.

Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.